According to reports from Business Standard, Omkar Pharmachem reported a standalone net loss of ₹0.01 crore in the quarter ended June 2026, marking a decline from the net profit of ₹0.03 crore recorded in the corresponding quarter of the previous financial year. This represents a shift from profitability to a marginal loss position for the pharmaceutical company. The company's financial results were approved by the board on August 13, 2026, as reported by multiple sources.
As reported by Business Standard, the company reported no sales during the quarter ended June 2026, which was also the case for the same quarter in the previous financial year. This absence of revenue generation contributed to the company's overall financial performance during this period.
According to the financial data reported by Business Standard, the company's financial position showed a reversal from the previous year's performance. The net profit of ₹0.03 crore recorded in Q1 FY26 had turned into a net loss of ₹0.01 crore in the corresponding quarter of the current financial year, indicating a challenging operating environment for the pharmaceutical company.
According to latest market data, Omkar Pharmachem has a market capitalization of ₹15.4 crore, which has declined by 40.6% over the past year. The company reported revenue of ₹0.47 crore and profit of ₹0.12 crore for the trailing twelve months. Despite reporting repeated profits, the company has not paid dividends to shareholders, indicating a conservative approach to capital distribution. The stock is currently trading at 0.42 times its book value with a promoter holding of just 0.03%, reflecting low insider ownership.
